Study guide
10.6 Quality Assurance & Quality Control Programs
BCSCP Board Certified Sterile Compounding Pharmacist Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Overview, USP Standards & CSP Categories
1.1 BCSCP Exam Format, Eligibility, Scoring & 2024 Content Outline 1.2 USP <797> Scope, Core Philosophy & Regulatory Framework 1.3 USP <797> Categories 1, 2, and 3 CSP Classification 1.4 Immediate-Use CSPs: The 4-Hour Rule and Its Conditions
2 Chapter 2: Facilities, Engineering Controls & Cleaning
2.1 Cleanroom Architecture & ISO Classifications 2.2 Primary Engineering Controls (PECs) & Laminar Airflow Dynamics 2.3 Segregated Compounding Areas (SCAs) & Containment SCAs (C-SCAs) 2.4 HVAC Engineering Controls, Pressure Differentials & Air Exchange 2.5 Equipment & Materials in Classified Areas Under Dynamic Conditions 2.6 Cleaning, Disinfecting, Sporicidal Agents & Sterile 70% IPA 2.7 Contingency Planning: Power, HVAC, Supply and Staffing Failures
3 Chapter 3: Environmental Monitoring & Facility Certification
3.1 Viable Airborne Microbial Monitoring 3.2 Total Airborne Non-Viable Particle Counting & Cleanroom Certification Standards 3.3 Surface Microbial Sampling: Contact Plates, Swabs, Incubation Protocols & Action Levels 3.4 Environmental Sampling Excursions, Trend Analysis, and Remediation Protocols
4 Chapter 4: Hand Hygiene, Garbing & Aseptic Technique
4.1 Hand Hygiene & Cleansing Protocols 4.2 Step-by-Step Garbing Sequence & Ante-Room Logistics 4.3 Direct Compounding Area (DCA) Aseptic Technique & First Air Integrity
5 Chapter 5: Beyond-Use Dating, Storage & Container Rules
5.1 Category 1 Beyond-Use Dating & Storage Limitations 5.2 Category 2 Beyond-Use Dating: Sterile vs. Nonsterile Starting Components 5.3 Category 3 Beyond-Use Dating: Requirements for Extended Dating (60/90/120 Days) 5.4 Container Types, Puncture Limits & Multi-Dose Container Rules
6 Chapter 6: Sterilization, Release Testing & Hazardous Drug Compounding
6.1 Terminal Sterilization vs. Sterilizing Filtration 6.2 Release Testing: Sterility (USP <71>), Endotoxin (USP <85>) & Particulates (USP <788>) 6.3 Container Closure Integrity Testing (CCIT) & Visual Inspection 6.4 USP <800> Hazardous Drug Compounding & Closed System Drug-Transfer Devices (CSTDs)
7 Chapter 7: Materials, Equipment & Compounding Workflow
7.1 Compounding Equipment & Technology: ACDs, Balances, Pumps & IV Workflow Systems 7.2 Compounding Supplies, Containers & Closures 7.3 Component Receipt, Storage & Material Transfer 7.4 Calibration, Verification, Validation & Maintenance of Equipment 7.5 Compounding Workflow: SOPs, Workflow Software, Production Queues & Labeling 7.6 Handling, Storing, Packaging, Transporting & Disposing of Finished CSPs
8 Chapter 8: Calculations, Osmolarity & Physicochemical Compatibility
8.1 Sterile Compounding Calculations: Millimoles, Milliequivalents, Osmolarity & Tonicity Adjustments 8.2 Physical and Chemical Incompatibilities: pH Effects, Salt Formations & Precipitation Mechanisms 8.3 Complex Admixture Compatibility: Calcium-Phosphate Solubility Curves & Parenteral Nutrition Dynamics
9 Chapter 9: Therapeutics, Administration & Patient Monitoring
9.1 Patient-Specific Parameters: Verifying CSP Orders 9.2 Special Administration Routes: Epidural, Intrathecal, Ophthalmic & Intravesical Sterile Preparations 9.3 Medication Delivery Devices, Home Infusion & Patient Education 9.4 High-Alert Sterile Medications, Pediatric/Neonatal Considerations & Extravasation Management 9.5 Therapeutic Drug Monitoring, Catheter-Related Bloodstream Infection (CRBSI) Prevention & Clinical Vigilance 9.6 Medication Adherence in Home and Outpatient Sterile Therapy 9.7 Interprofessional Care Coordination for Sterile Preparations
10 Chapter 10: Quality Management, Records & Personnel Competency
10.1 Master Formulation Records (MFR) vs. Compounding Records (CR) Requirements & Workflow 10.2 Personnel Training, Core Competency & Written Testing Requirements 10.3 Gloved Fingertip and Thumb Sampling (GFT) Testing Cadence, Pass/Fail Thresholds & Action Plans 10.4 Media-Fill Testing Protocols: Simulation Design, Incubation Parameters & Failure Investigations 10.5 Standard Operating Procedures & Document Control 10.6 Quality Assurance & Quality Control Programs 10.7 Inspection Methods, Self-Audits & Continuous Readiness 10.8 Literature Evaluation: Research Methods, Statistics & Stability Evidence
11 Chapter 11: Regulatory Oversight, Accreditation & Drug Supply Chain
11.1 Drug Quality and Security Act (DQSA) & FDA Section 503A Traditional Pharmacies vs. Section 503B Outsourcing Facilities 11.2 State Boards of Pharmacy, FDA Guidance & Inter-Agency Regulatory Jurisdictions 11.3 Drug Supply Chain Security Act (DSCSA), Component Qualification & Certificate of Analysis (CoA) Verification 11.4 CMS, The Joint Commission, CDC, ASPEN & ASHP: Standards Beyond USP and FDA
12 Chapter 12: Safety Management, Investigations, Recalls & Waste
12.1 Root Cause Analysis (RCA), CAPA Framework & Out-of-Specification (OOS) Investigations 12.2 Adverse Drug Event Reporting, FDA MedWatch Form 3500 & Product Recall Protocols 12.3 Occupational Safety, Hazardous Waste Disposal (RCRA / EPA) & Spill Clean-up Management
10.6 Quality Assurance & Quality Control Programs
Key Takeaways Explain This Topic AI
USP <797> Section 18 requires formal, written QA and QC programs that ensure every part of CSP preparation meets the chapter and the law, with the roles, duties and training of QA staff described in the SOPs.
The designated person must ensure the program establishes a system of adherence to procedures, prevention and detection of errors and quality problems, evaluation of complaints and adverse events, and appropriate investigations and corrective actions.
USP's FAQ lists nine integrated QA components: training, SOPs, documentation, verification, testing, cleaning and safety, containers and labeling and storage, outsourcing (if used), and responsible personnel.
Quality control is the set of specific checks and tests (component checks, release inspection, sterility and endotoxin tests, environmental and personnel monitoring, equipment verification); quality assurance is the system that plans, reviews and improves them.
Outsourced CSPs are part of the program. A 503B supplier is qualified by its FDA registration, inspection and recall history, product testing and expiration data, and a written quality agreement.
Last updated: September 2026
10.6 Quality Assurance & Quality Control Programs
Every requirement in USP <797> produces data: fingertip plates, pressure logs, visual inspection results, sterility tests, complaints. A quality program turns those data into decisions. The BCSCP outline lists quality control programs (task 3A4) under quality management.
QA versus QC
Quality assurance (QA) Quality control (QC)
Focus The system : planning, procedures, review, improvement The checks and tests on products, processes and environment
Timing Continuous, forward-looking At defined points (in process, at release, on a schedule)
Examples SOP program, training program, trend review, CAPA, supplier qualification ACD accuracy check, visual inspection, sterility test, GFT, surface sampling
Question it answers "Will our process keep producing acceptable CSPs?" "Does this CSP, room or person meet specification right now?"
USP <797> Section 18 requirements
The facility's QA and QC programs must be formally established and documented in its SOPs . They must make sure that every part of CSP preparation meets USP <797> and the laws of the jurisdiction.
The designated person must make sure there are formal, written QA and QC programs that establish a system of:
- Adherence to procedures
- Prevention and detection of errors and other quality problems
- Evaluation of complaints and adverse events
- Appropriate investigations and corrective actions
The SOPs must describe the roles, duties and training of the people responsible for each part of the QA program.
Sections 18.1 to 18.3 add recall of out-of-specification CSPs, complaint handling and adverse event reporting (see 12.2).
USP's FAQ adds that a QA program should include nine integrated components : (1) training, (2) SOPs, (3) documentation, (4) verification, (5) testing, (6) cleaning, disinfecting and safety, (7) containers, packaging, repackaging, labeling and storage, (8) outsourcing, if used, and (9) responsible personnel.
QC activity map
- QC activity Minimum frequency or trigger Reference
- Order and component verification; calculation checks Every CSP USP <797> 9.3, 11
Visual inspection, label check, closure integrity check Every CSP before release; again before release if not dispensed the same day USP <797> 12.1
Sterility testing Category 2 CSPs that need it for their BUD; every Category 3 batch USP <797> 12.2
Bacterial endotoxin testing Injectables from nonsterile components when the BUD requires sterility testing; all Category 3 injectables from nonsterile components USP <797> 12.3
- Viable air sampling At least every 6 months (Category 1 and 2); monthly (Category 3) USP <797> 6.2
- Surface sampling At least monthly (Category 1 and 2); weekly plus after each batch (Category 3) USP <797> 6.3
- Certification and particle counts At least every 6 months USP <797> 5
- Pressure differentials Continuous monitoring; documented daily review USP <797> 4.2.5
GFT and media fill 3 initial garbing evaluations; every 6 months (Category 1 and 2) or 3 months (Category 3) USP <797> 2.2, 2.3
- ACD accuracy Before first use and each day of use USP <797> 9.1
- Storage temperatures Daily or continuous USP <797> 9.3.4, 19.1
- Cleaning documentation Each activity, per Table 10 USP <797> 7
- Quality metrics and trend review
Collecting data is not enough; USP <797> requires regular review for trends , and it requires environmental data to be looked at together with personnel data. A practical quality dashboard reviewed monthly by a quality committee might track:
- Environmental results by site, with alert and action excursions and the organisms recovered
- GFT and media-fill pass rates by person and by shift
- Errors and near misses caught by workflow technology, per 1,000 CSPs
- Sterility or endotoxin test failures and OOS investigations
- Complaints, adverse events and recalls
- Certification findings and pressure excursions
- On-time completion of SOP reviews and training
Use statistical process control (trend charts) to spot drift before an action level is breached, and feed the findings into CAPA (see 12.1). The plan-do-check-act cycle gives the structure: plan a change, test it, check the data, then standardize or adjust.
Outsourcing oversight
When a facility buys CSPs from a 503B outsourcing facility, those products are still part of its quality program. Qualify the supplier before first purchase and review it periodically:
- FDA registration as an outsourcing facility, and the products it reports making
- Inspection history : Forms 483, Warning Letters, recalls and import alerts
Quality agreement covering specifications, testing, expiration dating, change notification, complaints and recalls
- Certificates of analysis or test summaries for each lot, and confirmation that labels meet 503B requirements
- Receiving checks : shipping temperature, label, lot and expiration, physical inspection
- Performance data : complaints, delivery problems, shortages
State rules may add their own licensing requirements for out-of-state suppliers.
- Common audit findings
- Monitoring data collected but never reviewed or trended
- Excursions without a documented investigation or proof that the fix worked
- QA roles not defined in SOPs, or no deputy for the designated person
- Outsourced CSPs received with no supplier qualification file